Cytokinetics Q2 EPS $(1.34) Misses $(1.23) Estimate, Sales $867.00K Miss $2.50M Estimate
Portfolio Pulse from totan@benzinga.com
Cytokinetics (NASDAQ:CYTK) reported Q2 losses of $(1.34) per share, missing the analyst consensus estimate of $(1.23) by 8.94%. This is a 482.61% decrease over losses of $(0.23) per share from the same period last year. The company also reported quarterly sales of $867.00 thousand, missing the analyst consensus estimate of $2.50 million by 65.32%. This is a 99.03% decrease over sales of $88.97 million the same period last year.
August 04, 2023 | 2:21 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cytokinetics reported a significant decrease in Q2 earnings and sales, missing analyst estimates. This could negatively impact the company's stock price in the short term.
Cytokinetics reported a significant decrease in Q2 earnings and sales, missing analyst estimates. This underperformance is likely to negatively impact investor sentiment and could lead to a decrease in the company's stock price in the short term.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100